Literature DB >> 24801484

Block & replace regime versus titration regime of antithyroid drugs for the treatment of Graves' disease: a retrospective observational study.

Bijay Vaidya1, Ailsa Wright, Joanna Shuttleworth, Mollie Donohoe, Roderick Warren, Antonia Brooke, Christian A Gericke, Obioha C Ukoumunne.   

Abstract

CONTEXT: Two widely used antithyroid drug (ATD) regimes for Graves' disease (GD) include the 'block & replace' (B&R) regime (a fixed high-dose of ATD combined with levothyroxine) and the 'titration' regime (a titrating dose of ATD). Anecdotally, it is believed that B&R is less prone to fluctuating thyroid function.
OBJECTIVE: To study whether, in routine clinical practice, the B&R regime, compared with the titration regime, is associated with more stable thyroid function.
METHODS: We retrospectively analysed case-records for 450 patients treated with ATDs for GD at a secondary care hospital. Exclusion criteria included treatment with ATDs for <6 months, thyrotoxicosis due to other causes, treatment with radioiodine or thyroidectomy and pregnancy.
RESULTS: Two hundred and twenty three patients were treated with the B&amp;R regime ('B&amp;R group'), 149 with the titration regime ('titration group') and 78 with both regimes. The number of thyroid function tests (TFTs) performed per year (mean(SD): 3·2(1·2) vs 3·4(1·5); adjusted mean difference = -0·4; 95% CI: -0·7 to -0·1; and P = 0·008) and the number of hospital clinic visits per year (mean (SD): 2·9 (1·0) vs 3·2 (1·3); adjusted mean difference = -0·4; 95% CI: -0·7 to -0·2; and P = 0·002) were lower in the B&amp;R group than the titration group. The number of abnormal TFT results per year was similar in the two groups (mean(SD): 1·8(1·3) vs 1·8(1·4); adjusted mean difference = 0·05; 95%CI: -0·3 to 0·4; and P = 0·74).
CONCLUSIONS: In this retrospective study, there was little evidence that patients under B&amp;R have more stable thyroid function. Further data from prospective studies, however, are needed to confirm this finding.
© 2014 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24801484     DOI: 10.1111/cen.12478

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  8 in total

1.  Reflections on the Management of Graves' Hyperthyroidism.

Authors:  Chantal Daumerie; Jacques Orgiazzi
Journal:  Eur Thyroid J       Date:  2018-07-19

2.  Block-and-replace vs. titration antithyroid drug regimen for Graves' hyperthyroidism: two is not always better than one.

Authors:  L H Duntas
Journal:  J Endocrinol Invest       Date:  2020-09-30       Impact factor: 4.256

3.  Survey of Clinical Practice Patterns in the Management of 992 Hyperthyroid Patients in France.

Authors:  Bernard Goichot; Stéphane Bouée; Claire Castello-Bridoux; Philippe Caron
Journal:  Eur Thyroid J       Date:  2017-01-05

Review 4.  How to use thionamide anti-thyroid drug in the young- what's new?

Authors:  Tim Cheetham
Journal:  Thyroid Res       Date:  2021-07-21

5.  Epidemiology, management and outcomes of Graves' disease-real life data.

Authors:  Y S Hussain; J C Hookham; A Allahabadia; S P Balasubramanian
Journal:  Endocrine       Date:  2017-05-06       Impact factor: 3.633

6.  Hyperthyroidism in the personalized medicine era: the rise of mathematical optimization.

Authors:  Fanwen Meng; Enlin Li; Paul Michael Yen; Melvin Khee Shing Leow
Journal:  J R Soc Interface       Date:  2019-06-26       Impact factor: 4.118

7.  Effect of Addition of Thyroxine in the Treatment of Graves' Disease: A Systematic Review.

Authors:  Jun Li; Litao Bai; Fan Wei; Maoying Wei; Yao Xiao; Weitian Yan; Junping Wei
Journal:  Front Endocrinol (Lausanne)       Date:  2021-01-25       Impact factor: 5.555

8.  2022 European Thyroid Association Guideline for the management of pediatric Graves' disease.

Authors:  Christiaan F Mooij; Timothy D Cheetham; Frederik A Verburg; Anja Eckstein; Simon H Pearce; Juliane Léger; A S Paul van Trotsenburg
Journal:  Eur Thyroid J       Date:  2022-01-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.